CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04838301
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:13.537068+00:00
Published At: 2026-03-13T00:00:00+00:00
Record Updated At: 2026-03-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Alzheimer Dementia", "Late Onset Alzheimer Disease", "Neurodegenerative Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-13"
protocolSection.identificationModule.nctId: "NCT04838301"
protocolSection.identificationModule.officialTitle: "Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer\u0027s Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.